associ
sarcoidosi
risk
certain
occup
agricultur
employ
exposur
insecticid
moldi
environ
anoth
studi
note
hospit
admiss
african
american
sarcoidosi
south
carolina
increas
proxim
atlant
ocean
unifi
factor
environment
geograph
report
possibl
exposur
microbi
bioaerosol
natur
water
water
distribut
system
biofilm
pipe
peat
pot
soil
water
droplet
equip
bronchoscop
cathet
moldi
build
natur
habitat
environment
opportunist
mycobacteria
aerosol
environment
opportunist
mycobacteria
associ
develop
granulomat
diseas
mycobacteri
origin
hypersensit
pneumon
inabl
identifi
microorgan
histolog
stain
cultur
microorgan
patholog
tissu
continu
one
strongest
argument
potenti
role
infecti
agent
sarcoidosi
pathogenesi
molecular
analysi
continu
grow
sensit
specif
realiz
current
cultur
stain
method
identifi
less
two
percent
current
microbi
commun
present
within
human
biolog
specimen
advanc
molecular
techniqu
deep
sequenc
technolog
also
demonstr
success
identif
novel
microorgan
patholog
tissu
easili
identifi
tradit
method
molecular
analysi
patholog
tissu
microbi
nucleic
acid
protein
serv
altern
mean
identifi
put
infecti
agent
pcr
use
identifi
etiolog
agent
whippl
diseas
tropheryma
whippelii
well
novel
coronaviru
agent
sever
acut
respiratori
syndrom
sar
grow
scientif
interest
involv
defin
microbi
commun
within
distinct
diseas
ie
microbiom
analysi
microbiom
analysi
perform
upper
lower
airway
subject
interstiti
lung
diseas
includ
idiopath
interstiti
pneumonia
iip
noniip
sarcoidosi
well
pneumocysti
jiroveci
pneumonia
healthi
control
microbiota
lower
airway
major
patient
primarili
consist
prevotellacea
streptococcacea
acidaminococcacea
divers
measur
reveal
signific
differ
airway
microbiota
composit
five
differ
group
patient
conclud
iip
noniip
sarcoidosi
associ
disord
airway
microbiota
pathogen
role
commens
diseas
process
therefor
unlik
target
molecular
approach
microbi
pathogen
sarcoidosi
granuloma
strongli
support
propionibacteria
andor
mycobacteria
role
sarcoidosi
pathogenesi
japanes
research
report
molecular
evid
propionibacterium
acn
p
acn
dna
sarcoidosi
specimen
although
dna
could
also
isol
control
specimen
distinct
lie
quantit
differ
p
acn
dna
sarcoidosi
control
number
genom
p
acn
bronchoalveolar
lavag
bal
cell
correl
serum
angiotensinconvert
enzym
ace
level
percentag
macrophag
bal
fluid
patient
sarcoidosi
signific
differ
detect
p
granulosum
control
murin
model
sarcoidosi
pathogenesi
success
develop
use
heatkil
propionibacteria
intratrach
challeng
model
demonstr
contribut
tolllik
develop
polar
immun
respons
anoth
studi
confirm
role
p
acnesspecif
sarcoidosi
immun
respons
demonstr
p
acnesinduc
granulomat
pulmonari
inflamm
markedli
attenu
mice
compar
wildtyp
anim
recent
metaanalysi
involv
nine
casecontrol
studi
p
acn
associ
sarcoidosi
reveal
significantli
elev
sarcoidosi
risk
ci
investig
independ
laboratori
worldwid
also
report
molecular
evid
support
signific
associ
mycobacteria
sarcoidosi
one
studi
report
evid
mycobacteri
rrna
rna
polymeras
b
sarcoidosi
granuloma
none
control
p
chi
squar
sequenc
analysi
rrna
rpob
amplicon
reveal
presenc
novel
mycobacterium
genet
similar
mtb
complex
posit
ident
use
matrixassist
laser
desorptionion
time
flight
mass
spectrometri
song
et
al
found
mtb
katg
peptid
sarcoidosi
specimen
compar
control
specimen
situ
hybrid
local
mtb
katg
rrna
dna
insid
sarcoidosi
granuloma
analysi
polish
sarcoidosi
lymph
node
reveal
mtb
complex
heat
shock
protein
hsp
molecular
analysi
american
sarcoidosi
granuloma
also
reveal
presenc
nucleic
acid
mycobacteri
virul
factor
superoxid
dismutas
soda
sarcoidosi
specimen
compar
control
sequenc
analysi
amplicon
demonstr
close
posit
ident
mtb
complex
yet
genet
distinct
dna
mycobacteri
heat
shock
protein
detect
cutan
lesion
chines
sarcoidosi
patient
absent
control
specimen
sequenc
analysi
consist
mtb
chelona
gordona
anoth
studi
report
abil
realtim
pcr
analysi
quantit
differenti
sarcoidosi
tuberculosi
use
receiveroper
characterist
roc
curv
realtim
pcr
analysi
independ
laboratori
demonstr
viabl
mycobacteria
present
within
sarcoidosi
granuloma
present
sensit
acidfast
bacilli
afb
histolog
stain
futur
molecular
effort
delin
identifi
nucleic
acid
protein
reflect
activ
replic
organ
persist
protein
equal
import
modal
delin
infecti
agent
role
idiopath
diseas
assess
immun
respons
microbi
protein
presenc
humor
cellular
respons
microbi
antigen
insight
method
assess
exposur
infecti
agent
increas
lymphocyt
prolifer
induc
p
acn
report
patient
activ
sarcoidosi
howev
respons
correl
clinic
roentgenograph
physiolog
bronchoalveolar
lavag
find
regard
diseas
sever
sarcoidosi
immun
respons
viabl
p
acn
significantli
differ
healthi
control
recent
report
immun
respons
mycobacteria
also
report
along
detect
peptid
fragment
consist
katg
protein
within
sarcoidosi
granuloma
exist
humor
immun
respons
mycobacteri
katg
protein
demonstr
sarcoidosi
patient
song
et
al
note
igg
antibodi
recombin
mtb
katg
sera
sarcoidosi
patient
compar
sera
ppd
neg
control
sarcoidosi
character
polar
cell
immunophenotyp
identif
cellular
immun
respons
mycobacteri
katg
peptid
sarcoidosi
peripher
blood
mononuclear
cell
pbmc
suggest
sarcoidosi
immun
respons
may
mycobacteri
virul
factor
distinct
cellular
recognit
pattern
virul
factor
antigen
differenti
mycobacteri
speci
exampl
patient
infect
mtb
recogn
distinct
peptid
infect
lepra
investig
sarcoidosi
immun
respons
pattern
confirm
pattern
detect
distinct
patient
infect
mtb
lepra
anoth
report
demonstr
system
immun
respons
multipl
mycobacteri
virul
factor
sarcoidosi
patient
respons
multipl
secret
protein
also
multipl
epitop
within
given
protein
find
analog
observ
patient
activ
bacteri
infect
dual
molecular
immunolog
analysi
sarcoidosi
specimen
mycobacteri
virul
factor
superoxid
dismutas
demonstr
nucleic
acid
sequenc
closest
mtb
yet
distinct
translat
sequenc
peptid
stimul
sarcoidosi
pbmc
result
reproduct
sarcoidosi
immunophenotyp
mycobacteri
protein
soda
virul
factor
confer
pathogen
mycobacterium
speci
demonstr
protein
secret
system
requir
optim
secret
soda
katg
protein
synthes
without
sec
signal
sequenc
function
detoxifi
reactiv
oxygen
intermedi
roi
gener
host
macrophag
part
special
secret
system
contribut
virul
pathogen
mycobacteria
counter
oxid
attack
host
confer
abil
surviv
within
host
macrophag
addit
cell
immun
respons
mtb
katg
detect
sarcoidosi
bal
comparison
immun
respons
mycobacteri
katg
whole
protein
american
swedish
sarcoidosi
subject
reveal
differ
despit
distinct
patient
phenotyp
genet
prognost
characterist
also
demonstr
immun
respons
present
system
katgreact
cell
preferenti
accumul
lung
indic
compartment
respons
patient
without
syndrom
similar
frequenc
katg
specif
peripher
cell
studi
also
demonstr
circul
katgreact
cell
found
chronic
activ
sarcoidosi
patient
inact
diseas
loss
immun
respons
mycobacteri
virul
factor
celada
resolut
tuberculosi
also
observ
anoth
report
demonstr
immun
respons
mycobacteri
virul
factor
present
sarcoidosi
diagnost
bal
induct
innat
immun
tolllik
receptor
contribut
polar
immun
respons
recognit
significantli
absent
bal
fluid
cell
patient
lung
diseas
includ
infecti
granulomat
diseas
detect
immun
respons
katg
soda
confirm
exposur
sarcoidosi
patient
pathogen
mycobacteri
speci
protein
typic
secret
stage
activ
mycobacteri
replic
compar
express
protein
express
mycobacteria
latent
state
immunolog
analysi
perform
date
provid
mechan
indepth
analysi
sarcoidosi
pathogenesi
protein
use
delin
immunolog
pathway
contribut
sarcoidosi
resolut
diseas
progress
report
amyloid
precursor
protein
serum
amyloid
saa
strikingli
abund
sarcoidosi
tissu
predominantli
nonfibrillar
form
local
epithelioid
granuloma
saa
detect
numer
pulmonari
infect
tuberculosi
nontubercul
mycobacteria
ntm
infect
leprosi
comparison
quantit
immunohistochemistri
show
extent
distribut
saa
sarcoidosi
significantli
lower
diseas
granulomat
inflamm
chen
et
al
elabor
concept
chronic
stimul
innat
immun
system
disaggreg
host
protein
serum
amyloid
within
granuloma
follow
microbi
infect
induc
hyperimmun
immun
respons
microbi
antigen
absenc
ongo
infect
saa
level
reduc
pulmonari
tuberculosi
subject
follow
initi
antimicrobi
therapi
addit
antibodi
autoantigen
zinc
finger
protein
mitochondri
ribosom
protein
identifi
sarcoidosi
bal
serum
high
interindividu
heterogen
note
use
pulmonari
cell
patient
hladr
molecul
affin
purifi
bound
peptid
acid
elut
peptidi
separ
reversedphas
high
perform
liquid
chromatographi
analyz
liquid
chromatographymass
spectrometri
result
identif
autoantigen
vimentin
atp
synthas
data
support
immun
respons
self
antigen
present
local
system
site
sarcoidosi
subject
investig
sarcoidosi
immun
function
upon
cell
receptor
stimul
reveal
signific
distinct
healthi
control
presenc
chronic
immun
stimul
due
persist
microbi
antigen
report
reduc
cell
function
sarcoidosi
lymphocyt
also
character
reduc
cytokin
express
prolif
capac
well
upregul
inhibitori
receptor
program
immunolog
phenomena
associ
elev
antigen
burden
defin
wherri
colleagu
cell
exhaust
occur
result
chronic
antigen
stimul
durat
antigen
exposur
result
gradual
reduct
cell
abil
optim
respond
tcr
stimul
healthi
cell
produc
high
level
cytokin
exhibit
high
level
prolifer
low
level
apoptosi
respons
antigen
exhaust
cell
gradual
lose
normal
function
longer
respond
antigen
instead
undergo
apoptosi
upon
tcr
activ
upregul
cell
play
signific
role
acquisit
exhaust
phenotyp
inhibitori
coreceptor
signal
ligand
function
modul
toler
self
antigen
limit
robust
adapt
immun
respons
foreign
antigen
exhaust
cell
express
high
level
correl
well
systemat
loss
cellular
function
recent
find
upregul
dysfunct
sarcoidosi
cell
well
cell
granulomat
diseas
character
microbi
antigen
mtb
schistosomiasi
suggest
phenotyp
could
result
persist
antigen
exposur
upregul
program
receptor
reduc
prolif
capac
sarcoidosi
bronchoalveolar
lavag
bal
peripher
cell
recent
report
restor
sarcoidosi
cell
prolif
capac
healthi
control
level
appar
pathway
blockad
variou
mechan
interfer
cell
prolifer
well
describ
report
inhibit
cell
prolifer
block
cell
cycl
progress
suppress
transcript
substrat
recognit
compon
ubiquitin
ligas
complex
scf
bind
degrad
cdk
inhibitor
therebi
allow
continu
cell
cycl
cell
cycl
impedi
therefor
prolifer
hindranc
shown
result
erk
pathway
inactiv
inhibit
cell
prolifer
correl
increas
avail
repress
cdkactiv
phosphatas
engag
also
demonstr
attenu
cell
receptor
tcr
signal
prevent
activ
report
upregul
particularli
import
associ
emerg
human
lymphotrop
virus
epsteinbarr
viru
ebv
cytomegaloviru
cmv
virus
associ
sarcoidosi
pathogenesi
follow
public
molecular
immunolog
support
role
microorgan
sarcoidosi
pathogenesi
fungi
propionibacteria
mycobacteria
increas
number
case
report
clinic
trial
regard
efficaci
antimicrobi
therapi
numer
prior
report
tetracyclin
particularli
doxycyclin
minocyclin
publish
subject
cutan
sarcoidosi
although
minocyclin
antimicrobi
effect
propionibacterium
acn
mechan
action
felt
immunomodulatori
recent
report
efficaci
clarithromycin
efficaci
propionibacteria
mycobacteria
report
japanes
femal
system
sarcoidosi
conclus
delin
mechan
action
pend
fungal
antigen
also
report
contribut
sarcoidosi
pathogenesi
report
clinic
radiograph
improv
follow
administr
antifung
therapi
posaconazol
ketoconazol
without
corticosteroid
report
sloven
sarcoidosi
patient
author
conduct
openlabel
patientprefer
trial
steroid
methylprednisolon
antifung
agent
posaconazol
ketoconazol
steroidsantifung
agent
signific
clinic
radiograph
improv
detect
antifung
group
also
report
reduct
diseas
recurr
among
antifung
therapi
studi
limit
includ
lack
random
well
conduct
doubl
blind
fashion
two
clinic
trial
regard
efficaci
antimycobacteri
therapi
sarcoidosi
pathogenesi
report
doubl
blind
placebocontrol
investig
antimycobacteri
regimen
consist
concomit
levaquin
ethambutol
azithromycin
rifampin
clear
compar
placebo
conduct
subject
cutan
sarcoidosi
intentiontotreat
analysi
cleartreat
group
mean
sd
decreas
lesion
diamet
mm
compar
increas
mm
placebotr
group
p
clear
group
signific
reduct
granuloma
burden
experienc
mean
sd
declin
mm
lesion
sever
compar
declin
mm
placebo
group
p
observ
clinic
reduct
present
followup
period
transcriptom
analysi
sarcoidosi
cell
reveal
revers
pathway
associ
diseas
sever
enhanc
tcell
function
follow
tcell
receptor
stimul
addit
openlabel
investig
regimen
conduct
pulmonari
sarcoidosi
subject
fifteen
chronic
pulmonari
sarcoidosi
patient
forc
vital
capac
fvc
predict
enrol
primari
efficaci
endpoint
chang
absolut
fvc
baselin
complet
therapi
secondari
endpoint
chang
function
capac
measur
six
minut
walk
distanc
qualiti
life
assess
measur
st
georg
respiratori
questionnair
sgrq
patient
enrol
complet
week
therapi
complet
week
therapi
clear
regimen
associ
fvc
increas
liter
week
liter
week
respect
increas
meter
baselin
week
mean
score
valid
sgrq
improv
week
baselin
earli
trial
promis
futur
investig
mechan
antimicrobi
worka
antimicrobi
immun
modul
bothi
warrant
increas
impetu
current
sarcoidosi
research
translat
strong
basic
research
investig
innov
therapeut
impact
sarcoidosi
pathogenesi
hope
lead
cure
progress
date
strongli
support
advanc
toward
goal
